Are We There Yet? Roadmap(s) To Higher Quality AAV

Current limitations in AAV gene therapy manufacturing platforms often leave us making difficult tradeoffs between achieving the speed, flexibility, scale, and quality we ultimately need. To learn how current companies are evaluating and striving to overcome these tradeoffs in their technology and outsourcing partner selections, facility designs, and regulatory preparations, tune into this archived episode of Cell & Gene Live.

Anna Rose Welch, Director of Cell & Gene Collaborative, Craig Malzahn, Sr. Vice President of Technical Operations at REGENXBIO, and Andrew Tustian, Sr. Director - Viral Production Core at Regeneron, discussed what the AAV gene therapy space has learned about AAV quality so far and which quality-related advancements we’re on the brink of realizing in the near future.